15th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

15th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies is organized by Moffitt Cancer Center and will be held on Jan 19, 2019 at Disney's Grand Floridian Resort & Spa, Lake Buena Vista, Florida, United States of America.

The target audience for this medical event is hematologists, medical oncologists, pharmacists, fellows, residents, advanced practice professionals, oncology nurses and other healthcare professionals who are interested in this field. This CME Conference has been approved for a maximum of 6.00 AMA PRA Category 1 Credits.

Conference Description :
The 15th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies Conference is designed to present the most recent diagnostic and therapeutic advances and treatment options in hematologic malignancies to practicing hematologists, oncologists, pharmacists, advanced practice professionals and oncology nurses. This one-day interactive conference will cover AML, MDS, NHL, CLL and Myeloma  in a format that includes plenary lectures, case presentations and discussions. Ample time will be available for networking.

Hematologic malignancies are the types of cancer that affect blood, bone marrow and lymph nodes and account for 9.5% of new cancer diagnoses in the United States. Florida is home to 3.3 million seniors and this group carries the greatest burden of cancer. It’s critical that Florida oncologists be updated on new treatment and management therapies to meet the needs of this population.

Conference Objectives are :
• Identify and discuss novel treatment options available for patients with AML.
• Explain the role of transplant in patients with AML.
• Select the optimal use of the newer pharmaceutical agents in the treatment of Hodgkin’s lymphoma.
• Justify the role of molecular profiling in MDS
• Select the optimal management for patients with Philadelphia chromosome positive ALL.
• Identify the pros and cons of stem cell transplant in patients with high risk B cell non-Hodgkin’s lymphoma in first complete remission (CR).
• Describe the optimal use of novel agents in the management of patients with previously untreated CLL.
• Examine new drug therapies in the treatment of multiple myeloma.
• Describe therapeutic strategies for managing patients with myelofibrosis.
• Recognize the side effects associated with the newer agents used in the treatment of multiple myeloma and Hodgkin’s lymphoma.

Additional details will be posted as soon as they are available.